SI-BONE (SIBN) to Release Earnings on Monday

SI-BONE (NASDAQ:SIBN - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Monday, May 5th. Analysts expect SI-BONE to post earnings of ($0.24) per share and revenue of $45.13 million for the quarter. SI-BONE has set its FY 2025 guidance at EPS.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. The business had revenue of $49.00 million during the quarter, compared to analysts' expectations of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. On average, analysts expect SI-BONE to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SI-BONE Stock Up 0.1 %

SI-BONE stock opened at $14.41 on Monday. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE has a 12 month low of $11.70 and a 12 month high of $19.16. The stock has a market capitalization of $611.75 million, a PE ratio of -15.66 and a beta of 1.02. The business has a 50 day simple moving average of $15.00 and a 200-day simple moving average of $14.65.

Insider Activity at SI-BONE

In other news, insider Anthony J. Recupero sold 3,311 shares of the company's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the transaction, the insider now owns 284,555 shares in the company, valued at approximately $4,026,453.25. This represents a 1.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Michael A. Pisetsky sold 3,128 shares of the company's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the transaction, the senior vice president now owns 244,878 shares of the company's stock, valued at approximately $3,462,574.92. The trade was a 1.26 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,776 shares of company stock worth $96,644. Corporate insiders own 3.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on SIBN shares. Truist Financial reiterated a "buy" rating and set a $22.00 price target (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Needham & Company LLC boosted their price target on shares of SI-BONE from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SI-BONE currently has an average rating of "Buy" and a consensus target price of $24.40.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.